Diagnosis and Staging of CLL/SLL
At a Glance
CLL is often diagnosed with a blood test and flow cytometry, while SLL usually requires a lymph node biopsy and staging scans. Characteristic cell markers confirm the diagnosis, and Rai or Binet staging describes disease extent but does not alone determine when treatment starts.
Confirming a diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) involves looking at the specific “fingerprint” of your white blood cells.
Because CLL cells circulate heavily in the blood, many patients with CLL can be diagnosed with a simple blood draw [1][2]. However, if your abnormal cells are mostly confined to your lymph nodes (SLL), a blood test may not be enough. SLL typically requires a lymph node biopsy (removing a piece of tissue) and staging scans, such as a CT or PET scan, to map where the disease is located [3][4]. By contrast, standard CLL diagnosis and staging does not usually require CT scans or PET scans [5].
The Diagnostic “Fingerprint”
To confirm the diagnosis, doctors use a technology called flow cytometry (on blood) or immunohistochemistry (on tissue biopsy). These tests look for specific proteins, or markers, on the surface of your cells [1]. A diagnosis is usually confirmed when your cells show a very specific combination of markers:
- CD19 and CD20: These identify the cells as B-cells [6]. In CLL/SLL, the CD20 marker is typically “dim,” meaning there is less of it than on normal B-cells [7].
- CD5: This is a marker normally found on T-cells. Its abnormal presence on a B-cell is a hallmark sign of CLL/SLL [6].
- CD23: This is usually present (positive) in CLL/SLL and helps distinguish it from other types of lymphoma [7].
- CD200 and LEF1: These are highly specific to CLL. CD200 is found on almost all CLL cells, and LEF1 is a protein found inside the cell nucleus in about 98% of CLL/SLL cases [8][9].
Distinguishing CLL/SLL from Mantle Cell Lymphoma
One of the most important steps in diagnosis is making sure the condition isn’t Mantle Cell Lymphoma (MCL), which can look very similar under a microscope but often requires different, more immediate treatment [10][11].
To tell them apart, doctors look for Cyclin D1, a protein that is present in MCL but absent in CLL/SLL [12]. If there is any doubt, they may perform a FISH test to look for a specific genetic swap called a t(11;14) translocation, which is the definitive signature of Mantle Cell Lymphoma and is not found in CLL [10][13].
Clinical Staging: Rai and Binet
Once the diagnosis is confirmed, your doctor will determine the “stage” of the disease. While SLL often uses standard lymphoma staging (evaluating lymph node regions via imaging), CLL generally uses two clinical staging systems based heavily on physical exams and blood counts [2].
The Rai System (Common in the US)
The Rai system focuses on whether the disease has moved from the blood into the lymph nodes, liver, spleen, or affected the production of other blood cells [14].
- Rai 0 (Low Risk): You have a high white blood cell count (lymphocytosis) but no other physical signs [14].
- Rai I & II (Intermediate Risk): You have enlarged lymph nodes (Stage I) or an enlarged liver or spleen (Stage II) [14].
- Rai III & IV (High Risk): The abnormal cells are “crowding out” your bone marrow, leading to low red blood cells (anemia, Stage III) or low platelets (thrombocytopenia, Stage IV) [14].
The Binet System (Common in Europe)
The Binet system counts how many “areas” of lymph nodes are enlarged (such as the neck, armpits, groin, spleen, and liver) [14].
- Binet A: Fewer than 3 areas are enlarged [14].
- Binet B: 3 or more areas are enlarged [14].
- Binet C: Low red blood cells or low platelets are present, regardless of how many lymph node areas are affected [14].
Does Stage Equal Treatment?
It is vital to understand that stage alone does not perfectly determine when you start treatment [15]. Many people at an “intermediate” stage may still be monitored for years without treatment if they feel well and their blood counts are stable [16].
Doctors generally only recommend starting treatment when the disease becomes “active.” Signs of active disease include massive or rapidly growing lymph nodes, a quick doubling of your white blood cell count, or the development of symptomatic “B-symptoms” like drenching night sweats and weight loss [15][2].
Common questions in this guide
What tests are used to diagnose CLL?
How is SLL diagnosed differently from CLL?
What do CD5 and CD23 mean in CLL/SLL?
How do doctors rule out mantle cell lymphoma?
What do Rai and Binet stages mean?
Does a higher CLL/SLL stage mean I need treatment right away?
One line in your results can change your plan.
Where abnormal cells are mainly located can decide whether a blood test may be enough or a lymph node biopsy is typically needed. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on chronic lymphocytic leukemia/small lymphocytic lymphoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Atypical Chronic Lymphocytic Leukemia-The Current Status.
Robak T, Krawczyńska A, Cebula-Obrzut B, et al.
Cancers 2023; (15(18)) doi:10.3390/cancers15184427.
PMID: 37760396 - 2
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.
Hallek M
American journal of hematology 2025; (100(3)):450-480 doi:10.1002/ajh.27546.
PMID: 39871707 - 3
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.
Yoshino T, Tanaka T, Sato Y
Journal of clinical and experimental hematopathology : JCEH 2020; (60(4)):124-129 doi:10.3960/jslrt.19041.
PMID: 32249238 - 4
Tonsillar Hypertrophy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Mini-Review.
Al-Shibly R, Ali EA, Qasem NM, et al.
Cureus 2025; (17(11)):e96963 doi:10.7759/cureus.96963.
PMID: 41409907 - 5
The Pattern of Use of PET/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia.
Hod K, Tova Y, Gold O, et al.
Clinical lymphoma, myeloma & leukemia 2021; (21(8)):558-563 doi:10.1016/j.clml.2021.04.003.
PMID: 34011485 - 6
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.
Rawstron AC, Kreuzer KA, Soosapilla A, et al.
Cytometry. Part B, Clinical cytometry 2018; (94(1)):121-128 doi:10.1002/cyto.b.21595.
PMID: 29024461 - 7
Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Sun Y, Wang SA, Sun T
Cytometry. Part B, Clinical cytometry 2018; (94(1)):148-150 doi:10.1002/cyto.b.21512.
PMID: 28109040 - 8
Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia.
Sorigue M, Magnano L, Miljkovic MD, et al.
Cytometry. Part B, Clinical cytometry 2020; (98(5)):441-448 doi:10.1002/cyto.b.21849.
PMID: 31692239 - 9
Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas.
Rangan A, Reinig E, McPhail ED, Rech KL
Human pathology 2022; (121()):29-35 doi:10.1016/j.humpath.2022.01.001.
PMID: 35066013 - 10
[Pathologic characteristics of bone marrow for CD5 positive small B cell lymphoma].
Peng S, Zhu F, You S, et al.
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2016; (41(4)):374-9 doi:10.11817/j.issn.1672-7347.2016.04.006.
PMID: 27241147 - 11
Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms.
Starostka D, Kriegova E, Kudelka M, et al.
Cytometry. Part B, Clinical cytometry 2018; (94(4)):576-587 doi:10.1002/cyto.b.21607.
PMID: 29220870 - 12
Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall.
Qiu L, Xu J, Tang G, et al.
Human pathology 2022; (119()):59-68 doi:10.1016/j.humpath.2021.11.001.
PMID: 34767860 - 13
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t(11;14)(q13;q32)/CCND1-IGH: A Rare Variant Of Richter Transformation to Mantle Cell Lymphoma.
Zhao Y, McCracken J, Rehder C, Wang E
Clinical lymphoma, myeloma & leukemia 2022; (22(5)):e310-e313 doi:10.1016/j.clml.2021.10.017.
PMID: 34840090 - 14
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
American journal of hematology 2017; (92(9)):946-965 doi:10.1002/ajh.24826.
PMID: 28782884 - 15
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Hallek M, Cheson BD, Catovsky D, et al.
Blood 2018; (131(25)):2745-2760 doi:10.1182/blood-2017-09-806398.
PMID: 29540348 - 16
When and How Long to Treat Chronic Lymphocytic Leukemia?
Niemann CU, Varghese A, Munir T, et al.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e473656 doi:10.1200/EDBK-25-473656.
PMID: 40273385
This page is for informational purposes only and does not constitute medical advice. Your hematology team should interpret your blood tests, biopsy results, scans, and CLL/SLL stage in the context of your care.